简体中文 | 繁體中文 | English

Products & Services News

2026-10-28 15:06 Ant International CEO: Achieving Inclusion Is Critical to Re-Globalisation, and AI Will Accelerate It by Democratising Opportunities
2026-10-28 11:52 Airship Announces Next-Generation AI Capabilities to Deliver the Right Customer Experience in the Moment
2026-10-28 11:50 Cognite Spotlights UAE Industrial AI Momentum and Honors Regional Leaders at Impact World Tour Event in Abu Dhabi
2026-10-28 11:42 AHS Properties to Launch USD 1.3 Billion AHS Twin Towers, a Grade A Commercial Office Building on Sheikh Zayed Road
2026-10-28 11:25 KBRA Japan Receives Credit Rating Agency Registration From Japan Financial Services Agency
2026-10-28 11:10 DDN Selected to Modernize Research Data Infrastructure at UNSW Sydney
2026-10-28 10:14 NTT DATA Expands AI Factory Footprint Globally to Help Clients Scale AI from Pilots to Production
2026-10-28 10:06 Ant Group Upgrades LingGuang to 2.0, Turning Its AI Assistant into a Proactive Personal Agent
2026-10-28 10:04 SES and CANAL+ Strengthen Strategic Partnership Through 2040
2026-10-27 14:39 Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function
2026-10-27 14:11 SHOJO MANGA INFINITY: Moto Hagio, Ryoko Yamagishi and Waki Yamato - A Major Exhibition Tracing the Expanding Possibilities of Shojo Manga
2026-10-27 14:07 Agent Assurance by TestMu AI Is Now Generally Available, Letting Teams Test What Their AI Agents Actually Change
2026-10-27 11:14 OptionMetrics Exhibiting at Asia EQD
2026-10-27 10:58 Dubai Chambers Launches World's First Agentic AI Marketplace by a Chamber of Commerce
2026-10-27 10:50 TVS Motor Company Returns to EICMA With New Models for Europe
2026-10-27 10:49 Dubai Culture Opens Registration for ISEA2026 Dubai
2026-10-27 10:27 WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN
2026-10-27 10:10 Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function
2026-10-27 08:26 Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
2026-10-27 08:17 Chidamide Plus Nivolumab Shows Potential as New Standard of Care in Advanced Melanoma, Reducing Disease Progression Risk by 27% in Global Phase 3 Trial

Business Wire Weibo

Press Releases

Latest Releases